DFJ Esprit, a top-tier, European technology venture capital firm, is pleased to announce that portfolio company Oxford Immunotec (or “the Company”) has completed the first stage of a major new US$40 million Series ‘E’ funding round. The round, one of the world’s largest for a diagnostics company in 2007, was led by two new international investors, Clarus Ventures of the USA with Munich based Wellington Partners and has been provided in two stages. DFJ Esprit contributed a further $2.6 million this time, through its Prelude Trust plc fund.